The 10-second takeaway
For the quarter ended March 31 (Q1), Antares Pharma whiffed on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue shrank significantly. GAAP earnings per share.
Margins shrank across the board.
Antares Pharma notched revenue of $4.5 million. The five analysts polled by S&P Capital IQ expected revenue of $5.1 million on the same basis. GAAP reported sales were 34% lower than the prior-year quarter's $6.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.03. The three earnings estimates compiled by S&P Capital IQ forecast -$0.03 per share. GAAP EPS were -$0.03 for Q1 compared to $0.00 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 55.2%, much worse than the prior-year quarter. Operating margin was -75.2%, much worse than the prior-year quarter. Net margin was -75.3%, much worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $6.2 million. On the bottom line, the average EPS estimate is -$0.03.
Next year's average estimate for revenue is $28.4 million. The average EPS estimate is -$0.11.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 184 members out of 203 rating the stock outperform, and 19 members rating it underperform. Among 21 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 15 give Antares Pharma a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Antares Pharma is buy, with an average price target of $5.25.
Looking for alternatives to Antares Pharma? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add Antares Pharma to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.